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Since its ﬁrst report almost 20 years ago, the Global initiative in
chronic Obstructive Lung Disease (GOLD) has had amajor effect on COPD
management [1]. The GOLD system of classifying COPD has been widely
adopted both clinically and academically while the regularly updated
treatment recommendations has led to their promotion ahead of more
formal evidence-based documents like The National Institute for Health
and Clinical Excellence (NICE) guidelines [2]. Initially GOLD classiﬁed
COPD severity by the degree of FEV1 impairment, but now amore sophis-
ticated (and complex) approach stratiﬁes by symptom intensity (com-
monly using a cut-point of 2 on the modiﬁed MRC dyspnoea scale) and
on a history of exacerbations. The resultant 4£ 4 classiﬁcation of clinical
phenotypes from minimal symptoms without exacerbations to severe
symptoms and frequent/signiﬁcant exacerbations is graded A-D and has
been linked to both initial and subsequent treatment choices [3].
Helpful as these recommendations are, they have limitations.
Patients recruited in randomised controlled trials may not be ‘typical’
of those seen in primary care while stopping existing treatments to
permit study entry might affect the trial outcome [4,5]. The advent of
large comprehensive clinical databases lets us understand what
treatment is given to what type of patient and how effective that
therapy is in a ‘real world’ setting. To date the consensus is that
patients seen in primary care are (unsurprisingly) less severe than
those in secondary care and are over-treated relative to guideline rec-
ommendations [6]. However, until now we have lacked primary care
data about the characteristics of COPD patients when a new treat-
ment is initiated and how they subsequently progress as compared
to patients already receiving therapy.
This deﬁciency has been remedied by Halpin and colleagues [7]
who report an elegantly conducted and robust analysis of the UK-
based Optimum Patient Care Research Database which contains clini-
cal and prescribing information from 5.8 million socio-economically
and geographically diverse patients. Using an index date of January
2014, they identiﬁed 2 groups of COPD patients, 11,409 (cohort 1)
with established disease on treatment and 699 (cohort 2) who startedDOI of original article: http://dx.doi.org/10.1016/j.eclinm.2019.07.003
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terms of their baseline characteristics and level of co-morbidities
with approximately 45% falling into GOLD grade A, 25% grade B and
15% in the remaining 2 groups. These data emphasise the differences
in the distribution of GOLD grades depending on the source of the
data with fewer GOLD C patients being found in secondary care-
based observational cohorts [8]. Over the two years of follow up the
overall number of patients in each GOLD grade was similar in both
cohorts but it was encouraging to see that over 50% of grade D
patients who began treatment in 2014 moved to grades A or B by
2016. Overall the exacerbation rate was low at 0.30.4 events per
year, unlike patients seen in secondary care where exacerbations are
a key reason for referral and management. The most widely used
treatment was with long-acting inhaled antimuscarinic drugs in
keeping with GOLD recommendations, although almost half the
patients used inhaled corticosteroids which led to most of the per-
ceived over-treatment. Two factors mitigated this  the 20% inci-
dence of co-existing asthma in these patients and the fact that over-
treated patients tended to have higher exacerbation rates.
This study has considerable strengths. The use of spirometry for diag-
nosis, the lack of missing data, the repeated measurements of mMRC
score which permitted re-classiﬁcation of the GOLD grading, the avail-
ability of data about smoking status and use of robust statistics mark this
study out from many other COPD observational studies. Whether the
COPD Assessment Test would be a better way to stratify symptom inten-
sity than the mMRC remains unclear. Likewise, the degree to which
treating physicians were aware of GOLD guideline recommendations is
not known. Unfortunately, this population is not large enough to assess
important outcomes like hospitalisation andmortality rates.
The study by Halpin et al. illustrates that early (or possibly mild)
forms of COPD dominate in community practice. This is the sub-
group of patients where evidence for effective treatment is weakest
but where the greatest scope exists for intervening to prevent disease
progression [9]. Almost 1/3rd of patients had a blood eosinophil
count above 300 microL/ml, the threshold where corticosteroids are
likely to be effective [10] and which has been adopted in the latest
GOLD recommendations [3]. Ensuring that this new approach is
more widely adopted than its predecessors will need better informa-
tion about why doctors make the choices that they do when initiating
new therapy for this complex disease.Authors Contribution
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